PAR 1.96% 25.0¢ paradigm biopharmaceuticals limited..

Video: Paradigm Biopharmaceuticals (ASX:PAR) conducting Phase 3 osteoarthritis trial, page-20

  1. 5,957 Posts.
    lightbulb Created with Sketch. 1138
    lots of fund managers (if invested in their own funds i assume) dont take board seats directly... imagine anytime investors under their umbrella, or the fund itself, bought or sold shares, it would be disclosed to the market (when a director).... that would be an emotional Sh!t fight for many shareholders here i would imagine... wowsers... the collateral damage amongst these hot copper threads here would be insane
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.